I drank lemon balm tea every day for a week to see if it could reduce stress and aid digestion — here's my verdict
With this in mind, when I heard about the viral TikTok trend of drinking lemon balm tea to reduce stress and anxiety, I decided to give it a try for a week to see if I noticed any difference. Read on to find out what happened.
According to recent studies, lemon balm tea offers several benefits for both mental and physical well-being. Lemon balm is a fragrant herb from the mint family, characterized by its lemon-scented leaves. It has been found to have antiviral properties, as well as being anti-inflammatory.
One of the most well-researched benefits of consuming lemon balm is its calming effect on the nervous system. This is said to reduce feelings of stress, anxiety, and nervousness. As well as helping you feel less stressed, lemon balm is thought to boost your mood and improve cognitive function and memory.
Lemon balm is often used as a natural remedy for conditions such as insomnia and sleep disturbances, due to its calming properties. It's often paired with ingredients like camomile to help you fall asleep more easily and improve your overall sleep quality.
Lemon balm is sometimes used in natural remedies for colic thanks to its ability to soothe digestive issues. It can also help with bloating, indigestion, gas and stomach cramps.
Lemon balm is also used in topical ointments that treat cold sores (HSV-1) thanks to its antiviral properties.
Get instant access to breaking news, the hottest reviews, great deals and helpful tips.
As a reminder, while lemon balm tea is considered safe to drink for most people, you should always check with your doctor if you're on regular medication, or if you're pregnant or breastfeeding.
Possible side effects associated with the consumption of lemon balm include headaches, nausea, vomiting and diarrhea. If you notice any of these side effects, stop taking lemon balm immediately.
Was lemon balm tea the secret to feeling calmer? Here's what happened when I committed to drinking lemon balm tea every day for a week.
Before popping the kettle on, I had to find lemon balm to drink. I keep a fresh mint plant in my garden, so I assumed I'd be able to buy a lemon balm plant in my local supermarket, and that I'd be able to stew the leaves in my teapot.
Unfortunately, it was a little trickier to find, so I ended up having to buy dried leaves on the internet instead. I also found a 'happy' tea blend which contained lemon balm, turmeric and apple.
In my first few days, I committed to sipping lemon balm at my desk. I usually drink peppermint tea, and the lemon balm tasted very similar. Plus, this article gave me more of an excuse to step away from my desk for a tea break.
While I wasn't immediately feeling much calmer, I did need to pee more. As well as being full of antioxidants, drinking more tea means more water.
It was convenient that I was doing this challenge during a heatwave here in the UK, so sipping on a couple of cups of tea during the day helped me drink more water and avoid dehydration.
Plus, another benefit is that lemon balm tea is naturally caffeine-free. I found I was drinking less coffee, which is always a good thing, as too much leaves me feeling even more anxious.
By the end of the week, I was fully on board with lemon balm tea and could quite easily make the switch from peppermint. I liked the taste and switched to my 'happy tea' blend when I wanted something a little punchier.
I didn't notice any differences in my digestion, but I don't often suffer from bloating or indigestion.
While I'm not sure my nervous system felt any calmer, I did find that the ritual of stepping away from my desk and making a tea, or sitting down with one after getting my son to bed, helped me carve out moments of calm during a very busy day.
I'm going to continue sipping lemon balm tea, so maybe by the end of the month, I'll be an Instagram-perfect mum, finding calm in the chaos. Until then, I'll keep taking deep breaths when my toddler throws his dinner at the kitchen wall.
Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vogue
18 minutes ago
- Vogue
8 Best Pore Strips for a Congestion-Free T-Zone
When it comes to quick fixes for clogged pores, the best pore strips have long held a beloved spot in skin-care routines worldwide. There's something undeniably satisfying about peeling away a strip and seeing the visible evidence of impurities (think: blackheads and sebaceous filaments) lifted from your skin. Beyond their instant gratification, pore strips provide an effective way to deep-clean areas prone to blackheads, such as the nose, chin, and forehead. They act like a magnet, drawing out excess oil and debris that can clog pores and lead to breakouts. In the age of TikTok skin-care experts, pore strips have gotten a bad rep—but you don't have to toss away the category as a whole. 'Using pore strips occasionally isn't harmful, but frequent use can sometimes irritate the skin,' says board certified dermatologist Dr. Dara Spearman. Plus, the pore strips of 2025 are a far cry from their Y2K predecessors, which tore off skin with a vengeance—evolution in the category has led to gentler hydrocolloid and biocellulose patches that equally, if not more effective. Meanwhile, K-beauty alternatives offer sebum-melting oils and treatments that ditch adhesive patches altogether. Dr. Spearman adds, 'While traditional strips provide quick results, K-beauty techniques offer a gentler, long-term way to care for your pores. It really comes down to what works best for your skin.' Vogue's Favorite Sheet Masks In This Story While pore strips aren't a comprehensive solution for long-term skin health, their benefits as a targeted, affordable, and satisfying cleansing method remaining clear in between proper facial appointments—particularly when combined with consistent skin-care routines. Scroll to discover our favorite blackhead-beating nose and T-zone strips to unclog pores and leave skin feeling fresh. Best Hydrocolloid: Mighty Patch Nose Strips Mighty Patch Nose Strips $17 AMAZON
Business Upturn
35 minutes ago
- Business Upturn
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.
By Business Wire India Published on July 24, 2025, 21:59 IST Business Wire India ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S. 1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease. 2,3 The approval represents an important milestone for LEO Pharma's expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs. LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.1 ANZUPGO is an innovative steroid-free, topical pan-Janus kinase (JAK) inhibitor for adults with CHE.1 ANZUPGO inhibits the JAK-STAT pathway, specifically blocking the activity of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), and suppresses the various inflammatory responses that play a key role in the onset and subsequent flares of CHE.1,2,4 The FDA approval of ANZUPGO marks a significant milestone in LEO Pharma's strategy to expand its presence in the U.S. market and deliver purposeful innovation in skin health. In preparation for bringing ANZUPGO to the U.S. patients, LEO Pharma has significantly upscaled its operations across key functions – including a 50% increase in the sales force. 'ANZUPGOis a good example of how we transform a real need in the market into medicines that can help make a difference for people living with serious skin diseases such as CHE,' said Christophe Bourdon, CEO, LEO Pharma. 'After successfully launching ANZUPGOin several countries, we're proud to now bring this innovation to adult patients with moderate-to-severe CHE in the United States. The approval of ANZUPGO reinforces our commitment to investing in difficult-to-treat skin conditions to deliver new treatments to patients where the need is greatest. We're truly grateful to the patients and physicians who participated in our studies and helped make this approval possible.' CHE is a highly debilitating inflammatory skin disease that affects approximately one in ten adults worldwide, causing itchy, painful, blistered, or swollen skin that can interfere with daily activities.2,3,5,6 The FDA approval of ANZUPGO provides adults in the U.S. living with moderate-to-severe CHE with the first and only treatment option specifically approved for this skin disease, just as it will be the first and only topical pan-JAK-inhibitor on the U.S. market. 'Chronic hand eczema can be a very difficult disease for adults to manage, especially given the lack of treatment options in the U.S. until now,' said Robert Spurr, EVP and President, North America, LEO Pharma. 'As the first and only FDA-approved treatment specifically for CHE in the U.S., ANZUPGO further establishes our company's real commitment to bringing treatments to market that address unmet needs in medical dermatology.' The FDA approval is the latest regulatory milestone for ANZUPGO, following the European Commission (EC) approval in 2024 and several launches internationally, including Germany, Switzerland, the United Kingdom and the United Arab Emirates. *Ends* About ANZUPGO®(delgocitinib) Cream ANZUPGO® (delgocitinib) cream is currently FDA approved in the U.S. as the first and only treatment for chronic hand eczema (CHE). ANZUPGO is also approved in the European Union, United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or not advisable. ANZUPGO cream is also under investigation in other markets. Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended by the U.S. FDA.1 ANZUPGO cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.7 In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. The full U.S. FDA Prescribing Information and Medication Guide are available here: About Chronic Hand Eczema Chronic hand eczema (CHE) is defined as hand eczema (HE) that lasts for three or more months or relapses twice or more within a year.5,8 HE is one of the most common skin disorders of the hands and in a substantial number of patients, it can develop into a chronic condition.9 CHE affects approximately one in ten adults worldwide.2,3 It is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.6 The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome.2 CHE has been shown to cause psychological and functional burdens that impact patient quality of life,10,11 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities.12 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.13 About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit References ANZUPGO® (delgocitinib) cream. Prescribing Information. FDA. July 2025. Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. Quaade AS, Simonsen AB, Halling A-S, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population – A systematic review and meta-analysis. Contact Dermatitis. 2021;84:361–374. Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64:41-51. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233. Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1-e22. Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24 Suppl 3:1-20. Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991. Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168. Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626. MAT-84121 July 2025 View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Epoch Times
3 hours ago
- Epoch Times
Pediatrician Group That Recommends Weight Loss Medications for Children Receives Money From Manufacturers: Study
The American Academy of Pediatrics (AAP) has taken in millions from companies that manufacture a new class of weight loss drugs, raising concerns about the organization's endorsement of the drugs for children as young as 8 years old, researchers said in a new paper. The AAP, in guidelines released in 2023, recommended that doctors should offer children aged 12 and older glucagon-like peptide-1 receptor agonists (GLP-1) and other weight loss drugs. The guidelines, which AAP said it vetted, also said clinicians could offer the drugs to children aged 8 to 11.
